ORIC Pharmaceuticals, Inc.
ORIC
$13.87
$0.151.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.00% | -5.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.33% | 14.67% | |||
| Operating Income | -14.33% | -14.67% | |||
| Income Before Tax | -16.01% | -17.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.01% | -17.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.01% | -17.25% | |||
| EBIT | -14.33% | -14.67% | |||
| EBITDA | -14.44% | -14.95% | |||
| EPS Basic | -13.27% | -14.02% | |||
| Normalized Basic EPS | -13.31% | -13.99% | |||
| EPS Diluted | -13.27% | -14.02% | |||
| Normalized Diluted EPS | -13.31% | -13.99% | |||
| Average Basic Shares Outstanding | 2.41% | 2.81% | |||
| Average Diluted Shares Outstanding | 2.41% | 2.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||